CTNM · Company research
Contineum Therapeutics, Inc. Class A Common Stock (CTNM): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
22records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| CTNM Dec 2026 20.000 call (CTNM261218C00020000) Stock Price, News, Quote & History - Yahoo! Finance Canada | CTNM Dec 2026 20.000 call (CTNM261218C00020000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Contineum Therapeutics, Inc. (CTNM) Stock Price, News, Quote & History - Yahoo! Finance Canada | Contineum Therapeutics, Inc. (CTNM) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 14, 2026 | neutral | 0 | 0.6 |
| CTNM Downgraded by Baird -- Price Target Lowered to $14.00 - GuruFocus | CTNM Downgraded by Baird -- Price Target Lowered to $14.00 GuruFocus | View source ↗ | GuruFocus | Oct 14, 2026 | neutral | 0 | 0.6 |
| BMY Reports Mixed Phase III Trial Results, Stock Down | Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| BMY Reports Mixed Phase III Trial Results, Stock Down | Bristol Myers Squibb announced mixed Phase III results for admilparant in idiopathic pulmonary fibrosis, meeting its primary endpoint only at the 60-mg dose while failing at 120-mg, causing the stock to decline 2.6%. However, the company reported positive Phase III results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, demonstrating statistically significant improvement in progression-free survival. The mixed outcomes reflect uncertainty about admilparant's dose consistency despite favorable safety profiles. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.2 | 1 |
| Why Is Contineum Therapeutics Stock Falling Monday? - Benzinga | Why Is Contineum Therapeutics Stock Falling Monday? Benzinga | View source ↗ | Benzinga | Oct 12, 2026 | neutral | 0 | 0.6 |
| All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy | Contineum Therapeutics, Inc. (CTNM) has been upgraded to a Zacks Rank #2 (Buy) rating based on upward trends in earnings estimates. The upgrade reflects positivity about the company's earnings outlook and positions it in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 1 | 1 |
| $CTNM stock is down 29% today. Here's what we see in our data. - Quiver Quantitative | $CTNM stock is down 29% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 12, 2026 | neutral | 0 | 0.6 |
| CTNM Stock Slides As Key Depression Drug Misses Trial Goal - StocksToTrade | CTNM Stock Slides As Key Depression Drug Misses Trial Goal StocksToTrade | View source ↗ | StocksToTrade | Oct 12, 2026 | neutral | 0 | 0.6 |
| Understanding the Setup: (CTNM) and Scalable Risk - Stock Traders Daily | Understanding the Setup: (CTNM) and Scalable Risk Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 7, 2026 | neutral | 0 | 0.6 |
| Contineum Therapeutics Inc (CTNM-Q) Stock Price and News - The Globe and Mail | Contineum Therapeutics Inc (CTNM-Q) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 1, 2026 | neutral | 0 | 0.6 |
| A 4,170-share sale is proposed by Contineum Therapeutics (CTNM) officer Daniel Lorrain. - Stock Titan | A 4,170-share sale is proposed by Contineum Therapeutics (CTNM) officer Daniel Lorrain. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| $CTNM stock is down 11% today. Here's what we see in our data. - Quiver Quantitative | $CTNM stock is down 11% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 15, 2026 | neutral | 0 | 0.6 |
| CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection? - Stocktwits | CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection? Stocktwits | View source ↗ | Stocktwits | Sep 14, 2026 | neutral | 0 | 0.6 |
| Johnson & Johnson's depression drug trial misses its goal - Stock Titan | Johnson & Johnson's depression drug trial misses its goal Stock Titan | View source ↗ | Stock Titan | Sep 14, 2026 | neutral | 0 | 0.6 |
| Contineum Therapeutics schedules a Sept. 15 fireside chat at 5:35 p.m. - Stock Titan | Contineum Therapeutics schedules a Sept. 15 fireside chat at 5:35 p.m. Stock Titan | View source ↗ | Stock Titan | Aug 25, 2026 | neutral | 0 | 0.6 |
| Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth - Simply Wall Street | Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth Simply Wall Street | View source ↗ | Simply Wall Street | Jul 17, 2026 | neutral | 0 | 0.6 |
| Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice - Yahoo Finance | Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice Yahoo Finance | View source ↗ | Yahoo Finance | Jul 9, 2026 | neutral | 0 | 0.6 |
| Insider Sale: CEO and President of $CTNM Sells 2,500 Shares - Quiver Quantitative | Insider Sale: CEO and President of $CTNM Sells 2,500 Shares Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 8, 2026 | neutral | 0 | 0.6 |
| CTNM Forecast — Price Target — Prediction for 2027 - TradingView | CTNM Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference - Business Wire | Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference Business Wire | View source ↗ | Business Wire | Jun 1, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Apr 6, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.